| Literature DB >> 29682579 |
Pedro Romero-Aroca1, Marc Baget-Bernaldiz1, Raul Navarro-Gil1, Antonio Moreno-Ribas2, Aida Valls-Mateu2, Ramon Sagarra-Alamo3, Joan F Barrot-De La Puente4, Xavier Mundet-Tuduri5.
Abstract
AIMS: To determine the relationship between diabetic nephropathy and diabetic retinopathy on a population of type 2 diabetes mellitus patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29682579 PMCID: PMC5846354 DOI: 10.1155/2018/5637130
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Descriptive and frequency values of the sample.
| Year | Number of subjects screened ( | Gender: men (%) | Mean age (years) | Diabetes duration (years) | Mean level of HbA1c % mean ± SD (min–max) |
|---|---|---|---|---|---|
| 2007 | 4910 | 2881 (57.31) | 64.62 ± 12.23 | 8.37 ± 6.92 | 7.37 ± 1.48 (3.9–14) |
| 2008 | 4873 | 2802 (56.16) | 66.27 ± 12.32 | 8.66 ± 6.78 | 6.82 ± 1.24 (4.3–12) |
| 2009 | 5191 | 2890 (54.41) | 65.39 ± 12.41 | 8.57 ± 6.12 | 7.02 ± 1.7 (3.8–15) |
| 2010 | 5243 | 3007 (56.03) | 65.69 ± 11.7 | 8.23 ± 6.81 | 7.47 ± 1.5 (4.5–14.5) |
| 2011 | 5264 | 2933 (55.60) | 65.22 ± 12.12 | 8.29 ± 6.56 | 7.3 ± 1.5 (4–15.5) |
| 2012 | 6193 | 3594 (56.72) | 65.33 ± 12.08 | 8.23 ± 6.82 | 7.63 ± 1.4 (4.3–15.8) |
| 2013 | 5494 | 3131 (55.69) | 65.87 ± 12.07 | 8.28 ± 6.11 | 7.62 ± 1.41 (4.3–15.8) |
| 2014 | 5983 | 3511 (57.33) | 65.88 ± 11.94 | 8.34 ± 6.83 | 7.64 ± 1.4 (4–15.6) |
| 2015 | 5026 | 2817 (56.05) | 65.84 ± 12.39 | 8.35 ± 6.77 | 7.61 ± 1.5 (4.2–15) |
| 2016 | 5423 | 3036 (56) | 65.94 ± 12.27 | 8.32 ± 6.72 | 7.63 ± 1.4 (4.4–15.4) |
Descriptive values are presented as number or mean ± standard deviation (SD).
Incidence of diabetic retinopathy and renal diabetic disease.
| Year | Any-DR, | STDR, | DME, | eGFR < 60 ml/min/1.73, | UACR ≥ 30 mg/g, | UACR ≥ 300 mg/g and eGFR< 30 ml/min/1.73 m2, |
|---|---|---|---|---|---|---|
| 2007 | 390 (7.94) | 131 (2.6) | 104 (2.00) | 294 (5.98) | 343 (6.98) | 3 (0.06) |
| 2008 | 384 (7.88) | 125 (2.5) | 101 (2.02) | 290 (5.95) | 344 (7.06) | 2 (0.04) |
| 2009 | 411 (7.06) | 132 (2.48) | 112 (2.11) | 301 (5.79) | 363 (6.99) | 3 (0.06) |
| 2010 | 424 (8.05) | 134 (2.49) | 114 (2.12) | 309 (5.89) | 372 (7.09) | 4 (0.07) |
| 2011 | 407 (7.73) | 141 (2.67) | 110 (2.08) | 310 (5.89) | 368 (6.99) | 4 (0.07) |
| 2012 | 533 (8.6) | 170 (2.68) | 150 (2.36) | 353 (5.70) | 432 (6.97) | 4 (0.06) |
| 2013 | 489 (8.9) | 162 (2.88) | 135 (2.40) | 324 (5.89) | 390 (7.09) | 4 (0.07) |
| 2014 | 529 (8.84) | 174 (2.84) | 153 (2.49) | 357 (6.13) | 419 (7.01) | 5 (0.08) |
| 2015 | 415 (8.25) | 139 (2.76) | 122 (2.42) | 301 (5.98) | 351 (6.98) | 4 (0.07) |
| 2016 | 484 (8.92) | 144 (2.65) | 114 (2.10) | 314 (5.79) | 385 (7.09) | 3 (0.05) |
Statistical analysis at the end of the ten-year follow-up study.
| Variables | Category | Mean values | Univariate statistical study significance |
|---|---|---|---|
| Age (years) | No diabetic retinopathy | 62.53 ± 13.63 |
|
| Diabetic retinopathy | 71.94 ± 10.56 | ||
|
| |||
| Sex (male) | No diabetic retinopathy | 41.50% |
|
| Diabetic retinopathy | 58.50% | ||
|
| |||
| Diabetes duration (years) | No diabetic retinopathy | 9.36 ± 6.58 |
|
| Diabetic retinopathy | 12.18 ± 6.21 | ||
|
| |||
| Arterial hypertension | No diabetic retinopathy | 49.53 |
|
| Diabetic retinopathy | 50.47 | ||
|
| |||
| Insulin treatment | No diabetic retinopathy | 18.54 |
|
| Diabetic retinopathy | 51.40 | ||
|
| |||
| HbA1c (%) | No diabetic retinopathy | 7.69 ± 2.69 |
|
| Diabetic retinopathy | 8.07 ± 1.76 | ||
|
| |||
| eGFR (ml/min/1.73 m2) | No diabetic retinopathy | 89.66 ± 16.11 |
|
| Diabetic retinopathy | 56.32 ± 12.20 | ||
|
| |||
| UACR (mg/g) | No diabetic retinopathy | 4.82 ± 43.00 |
|
| Diabetic retinopathy | 75.30 ± 231.26 | ||
∗Study made with two-tailed Student's t-test or ANOVA; F: Fisher-Snedecor distribution. ∗∗Study made with Chi-square; OR: odds ratio (95% CI).
Multivariate analysis using Cox's proportional regression analysis of any-diabetic retinopathy.
| Variables | Model 1∗ | Model 2∗∗ | Model 3∗∗∗ | Model 4∗∗∗∗ |
|---|---|---|---|---|
| Current age |
|
|
|
|
| HR 1.136 (1.084–1.224)† | HR 1.140 (1.081–1.227) | HR 1.140 (1.072–1.284) | HR 1.145 (1.083–1.290) | |
|
| ||||
| Sex |
|
|
|
|
| HR 0.761 (0.643–0.961) | HR 0.822 (0.668–1.060) | HR 0.820 (0.651–1.072) | HR 0.834 (0.644–1.015) | |
|
| ||||
| Insulin treatment |
|
|
|
|
| HR 1.218 (1.131–1.448) | HR 1.302 (1.188–1.506) | HR 1.311 (1.174–1.501) | HR 1.302 (1.178–1.545) | |
|
| ||||
| Arterial hypertension |
|
|
|
|
| HR 1.118 (0.985–1.788) | HR 1.121 (0.907–1.340) | HR 1.134 (1.002–1.161) | HR 1.367 (1.062–1.899) | |
|
| ||||
| HbA1c |
|
|
|
|
| HR 2.135 (1.893–2.408) | HR 2.089 (1.811–2.632) | HR 2.052 (1.780–2.273) | HR 2.037 (1.806–2.297) | |
|
| ||||
| eGFR < 60 ml/min/1.73 m2 |
|
|
| |
| HR 1.854 (1.251–4.431) | HR 1.223 (1.098–1.201) | HR 1.103 (0.078–1.311) | ||
|
| ||||
| UACR ≥ 30 mg/g |
|
| ||
| HR 1.485 (1.103–1.548) | HR 1.485 (1.092–1.465) | |||
|
| ||||
| UACR ≥ 300 mg/g and eGFR< 30 ml/min/1.73 m2 |
| |||
| HR 1.998 (1.682–2.305) | ||||
Model 1∗, Cox's analysis in which the variables of renal function are not included; model 2∗∗, Cox's analysis in which we include only the eGFR variable for the study of renal function; model 3∗∗∗, Cox's analysis with eGFR and UACR as variables for the study of renal function; model 4∗∗∗∗, Cox's analysis in which we included in addition to the eGFR and the UACR, the presence of renal failure. †Hazard ratio (95% CI).
Descriptive data of diabetic retinopathy forms.
| No-DR | STDR | Significance | DME | Significance | |
|---|---|---|---|---|---|
| Current age (years) | 64.01 ± 13.99 | 64.05 ± 12.27 |
| 64.36 ± 12.84 |
|
| DM duration (years) | 8.71 ± 6.12 | 13.91 ± 7.85 |
| 13.77 ± 7.78 |
|
| HbA1c (%) | 7.33 ± 1.76 | 9.21 ± 1.97 |
| 9.18 ± 1.96 |
|
| eGFR (<60 ml/min/1.73 m2) | 85.69 ± 20.31 | 73.32 ± 24.09 |
| 73.17 ± 24.20 |
|
| UACR (>30 mg/g) | 3.25 ± 55.33 | 66.68 ± 172.56 |
| 67.06 ± 173.78 |
|
STDR: sight threatening diabetic retinopathy; DME: diabetic macular edema; F = Fisher-Snedecor distribution.
Multivariate analysis using Cox's proportional regression analysis of STDR and DME.
| STDR | DME | |
|---|---|---|
| Variables | Significance | Significance |
| Hazard ratio (95% CI)∗ | Hazard ratio (95% CI) | |
|
| ||
| Current age |
|
|
| HR 0.991 (0.984–0.999) | HR 0.993 (0.986–1.000) | |
|
| ||
| Sex |
|
|
| HR 0.644 (0.531–0.781) | HR 0.655 (0.539–0.794) | |
|
| ||
| Insulin treatment |
|
|
| HR 1.313 (1.123–1.535) | HR 1.308 (1.117–1.530) | |
|
| ||
| Arterial hypertension |
|
|
| HR 2.128 (1.726–2.623) | HR 2.126 (1.721–2.626) | |
|
| ||
| HbA1c |
|
|
| HR 3.230 (2.378–4.387) | HR 3.194 (2.350–4.340) | |
|
| ||
| eGFR < 60 ml/min/1.73 m2 |
|
|
| HR 1.097 (0.899–1.979) | HR 1.033 (0.877–1.972) | |
|
| ||
| UACR ≥ 30 mg/g |
|
|
| HR 2.099 (1.163–3.072) | HR 1.978 (1.237–2.901) | |
|
| ||
| UACR ≥ 300 mg/g and eGFR < 30 ml/min/1.73 m2 |
|
|
| HR 3.174 (2.140–4.708) | HR 3.190 (2.150–4.732) | |
∗Hazard ratio (95% confidence interval). STDR: sight threatening diabetic retinopathy; DME: diabetic macular edema. ∗Hazard ratio (95%CI).
Figure 1Plots of risk function of Kaplan-Meier study. The y-axis represents the accumulative risk to develop diabetic retinopathy, and the x-axis represents diabetes mellitus duration in years. The green curve represents effect of patients with renal failure as risk factor, and the blue curve patients without renal failure. At the top, there is the analysis of renal failure measured with UACR ≥ 300 mg/g, and at bottom eGFR < 30 ml/min/1.73 m2.
Figure 2Plots of risk function of Cox study. The y-axis represents the accumulative risk to develop diabetic retinopathy, and the x-axis represents diabetes mellitus duration in years. The green curve represents the effect of patients with renal failure as a risk factor, and the blue curve patients without renal failure. At the top, there is the analysis of renal failure measured with UACR ≥ 300 mg/g, and at the bottom eGFR < 30 ml/min/1.73 m2.